Tirzepatide

Tirzepatide (LY3298176) Research Peptide – Dual GIP/GLP-1 Receptor Agonist, Metabolic & Obesity Research

39-Amino-Acid Lipidated Peptide for Incretin Signaling, Glucose Homeostasis, Appetite Regulation, Body Composition & Cardiometabolic Research

Tirzepatide, also known by its development code LY3298176, is a synthetic 39-amino-acid peptide that simultaneously activates the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R).

This dual-receptor pharmacology distinguishes tirzepatide from selective GLP-1 receptor agonists such as semaglutide.

Tirzepatide has been extensively investigated in clinical research involving type 2 diabetes, obesity, body composition, appetite regulation, glucose metabolism, obstructive sleep apnea and related cardiometabolic conditions.

It is the active ingredient in the FDA-approved prescription medicines Mounjaro and Zepbound, which have specific authorized indications and pharmaceutical quality requirements.

The availability of approved medicines containing tirzepatide does not establish the safety, efficacy, sterility or interchangeability of independently manufactured research-grade tirzepatide.

ICAME Pharmacy Tirzepatide is intended exclusively for legitimate laboratory and analytical research purposes.

FOR RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE.

What Is Tirzepatide?

Tirzepatide is a long-acting synthetic peptide developed to activate two important incretin hormone receptors.

These receptors are involved in regulating blood glucose, pancreatic hormone secretion, appetite and energy balance.

The two targets are:

GIPR — Glucose-Dependent Insulinotropic Polypeptide Receptor

GLP-1R — Glucagon-Like Peptide-1 Receptor

Both belong to the class B family of G protein-coupled receptors.

The peptide combines dual incretin receptor activation with a lipidated molecular structure that extends its duration of action.

Principal Research Areas

• GIP receptor pharmacology

• GLP-1 receptor pharmacology

• Dual incretin signaling

• Pancreatic beta-cell biology

• Glucose-dependent insulin secretion

• Glucagon regulation

• Appetite and satiety signaling

• Gastric emptying

• Energy intake

• Adipose tissue metabolism

• Obesity research

• Type 2 diabetes research

• Insulin resistance

• Body composition

• Liver fat metabolism

• Cardiometabolic risk factors

• Obstructive sleep apnea

• Peptide pharmacokinetics

• Receptor signaling bias

• Peptide lipidation and albumin binding

Tirzepatide is one of the most extensively clinically studied dual incretin receptor agonists.

Tirzepatide Molecular Structure and Chemical Properties

Tirzepatide is a synthetic 39-amino-acid peptide containing a lipidated side chain.

Its peptide backbone is based primarily on the sequence of GIP, with structural modifications designed to provide dual GIPR and GLP-1R agonism.

The molecule includes a C20 fatty diacid moiety attached through a linker to a lysine residue.

This lipid modification contributes to prolonged systemic exposure.

Molecular Characteristics

These molecular values refer to the defined tirzepatide molecule.

Salt forms, counterions, hydration and formulation components may alter the composition of a supplied preparation.

Tirzepatide Peptide Structure

Tirzepatide contains a modified 39-amino-acid peptide backbone.

Its structure includes noncanonical amino acid residues and a fatty diacid-linked side chain.

Key Structural Features

39 amino acid residues

GIP-derived peptide backbone

Dual GIPR and GLP-1R activity

Noncanonical amino acid substitutions

Lysine-linked C20 fatty diacid

Albumin-binding lipid modification

Extended pharmacokinetic profile

Why Is Lipidation Important?

Lipidation refers to the chemical attachment of a lipid-containing group to a molecule.

In tirzepatide, lipidation promotes reversible interaction with circulating albumin and contributes to prolonged exposure.

This is one reason approved tirzepatide medicines can be formulated for once-weekly administration.

Important Chemical Distinction

The C20 fatty diacid side chain is part of tirzepatide's molecular identity.

A peptide containing only the unmodified amino acid backbone is not chemically identical to tirzepatide.

What Are Incretin Hormones?

Incretins are gastrointestinal hormones that participate in the regulation of glucose metabolism after food intake.

Two major incretin hormones are:

Glucose-Dependent Insulinotropic Polypeptide (GIP)

Glucagon-Like Peptide-1 (GLP-1)

These hormones influence pancreatic hormone secretion and metabolic signaling.

Physiological Incretin Response

Nutrient Intake

↓

Intestinal Incretin Hormone Release

↓

GIPR and GLP-1R Activation

↓

Glucose-Dependent Insulin Secretion

↓

Changes in Glucagon Signaling

↓

Regulation of Postprandial Glucose

GLP-1 signaling also influences appetite and gastrointestinal physiology.

Tirzepatide is designed to engage both incretin receptor systems.

How Does Tirzepatide Work?

Tirzepatide activates both GIPR and GLP-1R.

These receptors are G protein-coupled receptors that signal predominantly through Gs-associated pathways.

Their activation stimulates adenylyl cyclase and increases intracellular cyclic adenosine monophosphate.

Dual-Receptor Mechanism of Action

Tirzepatide (LY3298176)

↙　　　　　　　　　↘

GIP Receptor (GIPR)　　 GLP-1 Receptor (GLP-1R)

↓　　　　　　　　　　　　 ↓

Gs Protein Activation

↓

Adenylyl Cyclase Stimulation

↓

Increased Intracellular cAMP

↓

PKA and EPAC Signaling

↓

Glucose-Dependent Insulin Secretion

↓

Improved Glucose Regulation

Additional effects involve appetite-related neural pathways, gastrointestinal function and broader metabolic responses.

The contributions of GIPR and GLP-1R signaling differ across tissues and experimental conditions.

Tirzepatide and GIP Receptor Research

GIP is an incretin hormone secreted primarily by intestinal K cells.

GIPR activation contributes to glucose-dependent insulin secretion.

Research Areas

GIPR binding

Gs protein signaling

cAMP accumulation

Pancreatic beta-cell function

Insulin secretion

Adipose tissue responses

Metabolic regulation

Receptor internalization

Receptor signaling bias

The exact contribution of GIPR agonism to tirzepatide's weight-reducing effects remains an active research topic.

Tirzepatide and GLP-1 Receptor Research

GLP-1 is an incretin hormone released primarily by intestinal L cells.

GLP-1 receptor signaling affects pancreatic hormone secretion, appetite and gastric emptying.

Research Areas

GLP-1R activation

Insulin secretion

Glucagon regulation

Appetite signaling

Satiety responses

Gastric emptying

Glucose homeostasis

Receptor trafficking

Intracellular signaling

Tirzepatide activates GLP-1R while also engaging GIPR.

This distinguishes it from selective GLP-1 receptor agonists.

Tirzepatide and cAMP Signaling

Cyclic AMP is an important intracellular second messenger.

Activation of GIPR and GLP-1R stimulates cAMP production.

Downstream Research Targets

Protein kinase A

Exchange protein directly activated by cAMP (EPAC)

Insulin granule exocytosis

Beta-cell signaling

Receptor desensitization

Receptor trafficking

Gene expression

Cellular metabolic responses

Experimental studies can investigate differences between tirzepatide and single-receptor agonists in these pathways.

Tirzepatide and Pancreatic Beta-Cell Research

Pancreatic beta cells produce insulin.

Insulin helps regulate blood glucose by influencing glucose uptake, storage and metabolism.

Tirzepatide enhances glucose-dependent insulin secretion.

Research Endpoints

Insulin secretion

Beta-cell responsiveness

cAMP signaling

Glucose-stimulated insulin secretion

Insulin processing

Islet function

Receptor expression

Metabolic stress responses

Glucose-dependent insulin secretion is a defining feature of incretin receptor pharmacology.

However, hypoglycemia can still occur, particularly when approved tirzepatide medicines are used with insulin or insulin secretagogues.

Tirzepatide and Glucagon Regulation

Glucagon is produced by pancreatic alpha cells.

It plays an important role in maintaining glucose availability.

Tirzepatide can influence glucagon responses in a glucose-dependent manner.

Research Areas

Pancreatic alpha-cell function

Glucagon secretion

Hepatic glucose production

Postprandial metabolism

Insulin–glucagon balance

Glucose homeostasis

The relationship between GIP signaling, GLP-1 signaling and glucagon is complex.

Tirzepatide should not be described simply as suppressing glucagon under every physiological condition.

Tirzepatide and Appetite Regulation

Appetite regulation involves interactions among gastrointestinal hormones, the central nervous system and metabolic signals.

Tirzepatide has been shown to reduce energy intake.

Research Areas

Hunger

Satiety

Food intake

Appetite-related neural signaling

Meal-related responses

Energy balance

Body weight regulation

Changes in appetite and energy intake contribute to the substantial weight reductions observed in clinical trials.

Tirzepatide and Gastric Emptying

Gastric emptying refers to the movement of stomach contents into the small intestine.

GLP-1 receptor agonism can delay gastric emptying.

Tirzepatide also delays gastric emptying, particularly after initial exposure.

The magnitude of this effect can diminish with repeated administration.

Research Areas

Gastrointestinal motility

Postprandial glucose

Nutrient absorption

Satiety

Drug absorption

Receptor adaptation

Delayed gastric emptying is also relevant to adverse effects and interactions with certain orally administered medicines.

Tirzepatide and Obesity Research

Obesity is a chronic disease involving complex interactions among energy balance, genetics, neuroendocrine signaling and environmental factors.

Tirzepatide has been extensively investigated in phase 3 clinical trials involving obesity.

Research Endpoints

Percentage body weight change

Absolute weight change

Waist circumference

Body composition

Cardiometabolic risk factors

Patient-reported outcomes

Long-term weight maintenance

Obesity-associated complications

The SURMOUNT clinical development program provides substantial evidence regarding tirzepatide's effects on body weight.

SURMOUNT-1 Clinical Trial: Tirzepatide and Weight Reduction

SURMOUNT-1 was a phase 3 randomized, double-blind, placebo-controlled study involving 2,539 adults with obesity or overweight and a weight-related complication, without diabetes.

The study evaluated weight change over 72 weeks.

Mean Percentage Body Weight Change at Week 72

These results were reported in the original 2022 publication.

Scientific Interpretation

Tirzepatide produced substantial, dose-dependent average weight reductions compared with placebo.

However, individual responses varied.

These findings relate to a regulated pharmaceutical product used under clinical trial conditions.

They do not establish the safety or efficacy of research-grade tirzepatide.

Tirzepatide and Long-Term Weight Maintenance

Weight regain after discontinuation is an important consideration in obesity research.

The SURMOUNT-4 trial investigated continued tirzepatide treatment compared with withdrawal to placebo following an initial treatment period.

Principal Findings

Participants who continued tirzepatide generally maintained or increased their weight reduction.

Participants switched to placebo experienced substantial weight regain on average.

Research Implications

Obesity is a chronic condition.

Treatment discontinuation can result in weight regain.

Long-term outcomes differ from short-term weight-loss measurements.

Maintenance strategies are an important part of clinical obesity management.

The trial does not support the idea that a short course of tirzepatide permanently resets body weight.

Tirzepatide and Type 2 Diabetes Research

Type 2 diabetes involves impaired insulin action and progressive abnormalities in glucose regulation.

Tirzepatide has been investigated extensively in the SURPASS clinical trial program.

Research Areas

HbA1c

Fasting plasma glucose

Postprandial glucose

Insulin secretion

Insulin sensitivity

Body weight

Hypoglycemia

Cardiometabolic risk factors

The SURPASS trials established substantial glucose-lowering effects in adults with type 2 diabetes.

SURPASS-2: Tirzepatide vs. Semaglutide

SURPASS-2 was a phase 3 trial comparing tirzepatide with semaglutide 1 mg in adults with type 2 diabetes receiving metformin.

The study evaluated changes in HbA1c over 40 weeks.

Mean HbA1c Reduction

Scientific Interpretation

All three tirzepatide groups achieved greater average HbA1c reductions than semaglutide 1 mg in this trial.

However, this was a comparison with a specific semaglutide dose in a specific diabetes population.

The results should not be presented as proof that tirzepatide is superior to every semaglutide formulation for every clinical outcome.

Tirzepatide and Insulin Resistance

Insulin resistance is a major component of type 2 diabetes and metabolic dysfunction.

Tirzepatide influences glucose regulation through multiple pathways.

Research Areas

Glucose-dependent insulin secretion

Body weight reduction

Adipose tissue biology

Hepatic metabolism

Insulin sensitivity

Postprandial glucose

Metabolic biomarkers

Weight reduction may contribute to improvements in insulin sensitivity.

However, not all metabolic effects can be attributed exclusively to weight loss.

Tirzepatide and Body Composition

Body composition includes fat mass, lean mass and other tissue compartments.

Tirzepatide-associated weight reduction includes decreases in fat mass and lean mass.

Research Areas

Total fat mass

Visceral adipose tissue

Subcutaneous fat

Lean mass

Waist circumference

Fat distribution

Muscle function

Important Consideration

Loss of lean mass can accompany substantial weight reduction.

A reduction in body weight should not automatically be interpreted as exclusive fat loss.

Tirzepatide and Visceral Fat Research

Visceral adipose tissue is located within the abdominal cavity.

Excess visceral fat is associated with several metabolic risk factors.

Research Areas

Visceral adipose tissue volume

Abdominal fat distribution

Waist circumference

Insulin resistance

Inflammatory biomarkers

Metabolic risk

Tirzepatide-associated weight reduction can include decreases in visceral fat.

The extent of these changes depends on the study population and measurement method.

Tirzepatide and Liver Fat Research

Metabolic dysfunction-associated steatotic liver disease, or MASLD, is characterized by hepatic steatosis associated with cardiometabolic risk factors.

Tirzepatide has been investigated for effects on hepatic fat and liver-related outcomes.

Research Areas

Liver fat fraction

Hepatic steatosis

Liver enzymes

Insulin resistance

Inflammatory markers

Body composition

Liver histology

Evidence from clinical trials has generated substantial interest in tirzepatide's potential role in metabolic liver disease.

However, liver-related outcomes and regulatory indications should be distinguished from its established diabetes and obesity indications.

SYNERGY-NASH: Tirzepatide and MASH Research

The phase 2 SYNERGY-NASH trial evaluated tirzepatide in adults with metabolic dysfunction-associated steatohepatitis and moderate or severe fibrosis.

The study assessed liver histology after 52 weeks.

MASH Resolution Without Worsening of Fibrosis

Scientific Interpretation

Tirzepatide demonstrated promising histological effects in this phase 2 study.

However, the findings do not establish that all patients will experience MASH resolution or fibrosis improvement.

Longer-term clinical outcomes require further evaluation.

Tirzepatide and Obstructive Sleep Apnea Research

Obstructive sleep apnea is characterized by repeated episodes of upper airway obstruction during sleep.

Obesity is an important risk factor.

Tirzepatide has been investigated in adults with obesity and moderate-to-severe obstructive sleep apnea.

Research Endpoints

Apnea–hypopnea index

Body weight

Sleep-related oxygen measurements

Cardiometabolic markers

Patient-reported sleep outcomes

Disease severity

The SURMOUNT-OSA clinical program demonstrated clinically meaningful improvements in sleep apnea severity in the studied population.

FDA Regulatory Status

Zepbound is FDA-approved for treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, alongside a reduced-calorie diet and increased physical activity.

This indication is specific to the approved prescription medicine.

Tirzepatide and Cardiometabolic Research

Cardiometabolic health involves glucose metabolism, lipid regulation, blood pressure, adiposity and cardiovascular physiology.

Research Areas

HbA1c

Fasting glucose

Triglycerides

Blood pressure

Body weight

Waist circumference

Insulin resistance

Inflammatory biomarkers

Cardiovascular outcomes

Clinical improvements in metabolic risk markers should be distinguished from demonstrated effects on major cardiovascular events.

Specific cardiovascular outcomes require direct clinical trial evidence.

Tirzepatide and Kidney Research

Type 2 diabetes and obesity are associated with increased risk of chronic kidney disease.

Tirzepatide has been investigated for kidney-related endpoints.

Research Areas

Albuminuria

Estimated glomerular filtration rate

Metabolic risk factors

Blood pressure

Inflammatory signaling

Renal outcomes

Some clinical analyses have suggested favorable kidney-related signals.

However, kidney protection should not be inferred solely from improvements in glucose or body weight.

Tirzepatide and Inflammation Research

Obesity and metabolic dysfunction can be associated with chronic low-grade inflammation.

Tirzepatide has been investigated for changes in inflammation-related biomarkers.

Research Areas

C-reactive protein

Adipose tissue inflammation

Metabolic inflammation

Insulin resistance

Liver inflammation

Cardiometabolic signaling

Some changes may be secondary to weight loss and improved metabolic status.

Direct anti-inflammatory mechanisms remain an area of investigation.

Tirzepatide and Energy Expenditure

Body weight is influenced by both energy intake and energy expenditure.

Tirzepatide's clinical effects are strongly associated with reduced energy intake.

Research Areas

Appetite regulation

Caloric intake

Energy expenditure

Metabolic adaptation

Body composition

Weight maintenance

It would be inaccurate to claim that tirzepatide causes weight loss primarily by dramatically increasing resting energy expenditure.

Tirzepatide and Receptor Signaling Bias

Receptor signaling bias refers to differences in how a ligand activates downstream signaling pathways.

Tirzepatide has attracted research interest because its GLP-1 receptor signaling profile differs from that of native GLP-1 and some other agonists.

Research Areas

Gs protein activation

cAMP accumulation

Beta-arrestin recruitment

Receptor internalization

Receptor trafficking

Signal duration

Receptor desensitization

These mechanisms may contribute to differences in pharmacology, but their relative clinical importance remains under investigation.

Tirzepatide vs. Semaglutide

Tirzepatide and semaglutide are both incretin-based medicines.

However, their receptor targets differ.

Clinical Comparison

SURPASS-2 demonstrated greater average HbA1c reductions with tirzepatide than semaglutide 1 mg in the studied population.

Other trials have evaluated obesity-specific outcomes using different formulations and doses.

Cross-trial comparisons should be interpreted cautiously.

Tirzepatide vs. Retatrutide

Retatrutide is an investigational triple-receptor agonist targeting GIPR, GLP-1R and the glucagon receptor.

Tirzepatide

GIPR + GLP-1R

Retatrutide

GIPR + GLP-1R + GCGR

The addition of glucagon receptor agonism creates a different pharmacological profile.

The two peptides are not interchangeable.

Tirzepatide vs. Survodutide

Survodutide is an investigational dual GLP-1 and glucagon receptor agonist.

Tirzepatide targets GIPR and GLP-1R.

Tirzepatide

GIPR + GLP-1R

Survodutide

GLP-1R + GCGR

Although both activate GLP-1R, their second receptor targets differ.

This difference is relevant to research involving appetite, hepatic metabolism and energy balance.

Tirzepatide vs. Mazdutide

Mazdutide is a dual GLP-1 and glucagon receptor agonist.

Tirzepatide is a dual GIP and GLP-1 receptor agonist.

Main Difference

Tirzepatide: GIPR + GLP-1R

Mazdutide: GLP-1R + GCGR

The compounds have distinct receptor pharmacology and clinical development histories.

Regulatory status must be evaluated by country and date.

Tirzepatide vs. Cagrilintide

Cagrilintide is a long-acting amylin analogue investigated in weight-management research.

Tirzepatide is a dual incretin receptor agonist.

Tirzepatide

GIPR + GLP-1R signaling

Cagrilintide

Amylin receptor-associated signaling

The peptides target different endocrine pathways.

They are not interchangeable.

Tirzepatide vs. Liraglutide

Liraglutide is a GLP-1 receptor agonist.

Tirzepatide activates both GIPR and GLP-1R.

Principal Differences

Receptor selectivity

Molecular structure

Pharmacokinetic profile

Clinical trial evidence

Approved indications

Formulation characteristics

Clinical comparisons must account for the specific product, dose and study population.

Tirzepatide and FDA Approval

Tirzepatide is the active ingredient in FDA-approved prescription medicines.

Mounjaro

Mounjaro is an FDA-approved tirzepatide medicine used to improve glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise.

The precise age range and other requirements should be checked against the current prescribing information.

Zepbound

Zepbound is an FDA-approved tirzepatide medicine indicated, together with reduced-calorie diet and increased physical activity, for:

Long-term weight reduction and maintenance in eligible adults with obesity or overweight and a weight-related comorbidity

Treatment of moderate-to-severe obstructive sleep apnea in adults with obesity

Important Regulatory Distinction

These approvals apply to specific pharmaceutical products.

They do not establish approval of research-grade tirzepatide preparations.

Tirzepatide Safety Considerations

Approved tirzepatide medicines have defined contraindications, warnings and adverse reactions.

Common Adverse Reactions

Nausea

Diarrhea

Vomiting

Constipation

Abdominal discomfort

Dyspepsia

Decreased appetite

Important Warnings and Risks

Thyroid C-Cell Tumor Warning

FDA-approved tirzepatide products carry a boxed warning regarding thyroid C-cell tumors observed in rodents. The relevance to humans is uncertain.

They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Severe Gastrointestinal Adverse Reactions

Significant gastrointestinal symptoms can occur.

Pancreatitis

Acute pancreatitis has been reported.

Gallbladder Disease

Gallbladder-related adverse events can occur.

Hypoglycemia

Risk can increase when used with insulin or insulin secretagogues.

Acute Kidney Injury

Dehydration associated with gastrointestinal adverse reactions can contribute to kidney injury.

Hypersensitivity

Serious hypersensitivity reactions have been reported.

Diabetic Retinopathy

Patients with a history of diabetic retinopathy may require monitoring, particularly with rapid improvement in glucose control.

Pulmonary Aspiration During Anesthesia

Delayed gastric emptying may be relevant during procedures requiring general anesthesia or deep sedation.

Oral Medication Absorption

Tirzepatide can affect absorption of some orally administered medications.

Pregnancy

Weight-management use is not appropriate during pregnancy.

Research Product Considerations

Clinical safety data for approved formulations do not establish the safety of independently manufactured research-grade tirzepatide.

Tirzepatide and Oral Contraceptive Interactions

Tirzepatide delays gastric emptying.

This can affect the absorption of oral medications.

FDA prescribing information includes specific precautions regarding oral hormonal contraceptives.

This interaction is clinically relevant and should not be overlooked when interpreting the safety profile of approved tirzepatide medicines.

Tirzepatide and Long-Term Safety Research

Long-term treatment raises important scientific questions.

Research Areas

Weight maintenance

Body composition

Gastrointestinal tolerability

Gallbladder events

Pancreatic safety

Kidney function

Cardiovascular outcomes

Nutritional status

Quality of life

Treatment discontinuation

Long-term clinical benefits and risks must be assessed using appropriately designed studies.

Tirzepatide and Peptide Stability

Tirzepatide is a chemically modified peptide.

Its stability depends on molecular structure, formulation and environmental conditions.

Research Considerations

Hydrolysis

Oxidation

Deamidation

Aggregation

Adsorption

Temperature-associated degradation

pH-dependent changes

Lipid-associated interactions

Peptide impurity formation

Counterion composition

Product-specific stability claims require validated analytical evidence.

Tirzepatide Analytical Characterization

Accurate molecular identification is essential for reliable research.

Essential Analytical Parameters

Peptide sequence

Noncanonical amino acid residues

Lipid side-chain identity

Linker structure

Molecular mass

Peptide purity

Peptide content

Counterion composition

Related substances

Degradation products

Batch identification

Analytical methodology

A research product should not be assumed to be pharmaceutically equivalent to Mounjaro or Zepbound based only on the ingredient name.

High-Performance Liquid Chromatography

HPLC can be used to evaluate tirzepatide purity and related impurities.

Research Applications

Chromatographic purity

Related peptide analysis

Degradation monitoring

Batch consistency

Method validation

A high chromatographic purity result does not independently establish pharmaceutical quality.

Liquid Chromatography–Mass Spectrometry

LC-MS can assist in verifying tirzepatide molecular identity.

The expected molecular mass of the defined tirzepatide molecule is approximately 4,813.5 g/mol.

Mass spectrometry should be interpreted alongside sequence and structural characterization.

The lipidated side chain is an essential part of the molecular identity.

Peptide Content Analysis

Peptide content is distinct from HPLC purity.

A supplied preparation may contain:

The principal peptide

Counterions

Residual water

Related substances

Non-peptide impurities

Accurate peptide content is important for quantitative laboratory experiments.

Certificate of Analysis

A batch-specific Certificate of Analysis should include:

• Product identity

• Batch or lot number

• Molecular formula

• Molecular mass

• Peptide sequence

• Noncanonical amino acid modifications

• Lipid side-chain identification

• Peptide purity

• Peptide content

• Counterion information

• Impurity profile

• Analytical methods

• Stability information

A COA does not establish clinical efficacy, sterility or suitability for human administration.

Scientific Evidence: Established Findings and Limitations

Established Scientific Facts

• Tirzepatide is a synthetic 39-amino-acid peptide.

• It activates both GIPR and GLP-1R.

• Its molecular formula is C₂₂₅H₃₄₈N₄₈O₆₈.

• Its molecular weight is approximately 4,813.5 g/mol.

• It contains a C20 fatty diacid side chain.

• It stimulates glucose-dependent insulin secretion.

• It has demonstrated substantial HbA1c reductions in type 2 diabetes trials.

• It has demonstrated substantial weight reductions in obesity trials.

• It is the active ingredient in FDA-approved prescription medicines.

• Zepbound has an FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity.

• Tirzepatide has been investigated in MASH and other metabolic conditions.

Important Scientific Limitations

• Clinical outcomes vary across patients.

• Weight loss is not necessarily permanent after discontinuation.

• Weight reduction includes changes in lean mass as well as fat mass.

• Tirzepatide is not a universal treatment for every metabolic disease.

• Cardiovascular and renal claims must be supported by indication-specific evidence.

• Tirzepatide has clinically relevant contraindications and adverse effects.

• Approved pharmaceutical products are not interchangeable with research-grade preparations.

• ICAME Pharmacy Tirzepatide is not Mounjaro or Zepbound.

• Research-grade tirzepatide is not intended for human administration.

Potential Tirzepatide Research Applications

Tirzepatide may be relevant to appropriately controlled laboratory investigations involving:

• Dual incretin receptor pharmacology

• GIPR signaling

• GLP-1R signaling

• Class B GPCR biology

• Gs protein activation

• cAMP signaling

• PKA and EPAC pathways

• Pancreatic beta-cell function

• Glucose-dependent insulin secretion

• Glucagon regulation

• Glucose homeostasis

• Appetite-related signaling

• Gastric emptying

• Energy balance

• Adipose tissue metabolism

• Obesity-associated mechanisms

• Insulin resistance

• Body composition

• Hepatic fat metabolism

• Cardiometabolic signaling

• Receptor trafficking

• Peptide lipidation

• Albumin binding

• Peptide stability

• Analytical peptide characterization

These research areas do not establish therapeutic benefits for ICAME Pharmacy research products.

Tirzepatide Research Overview

Compound Name: Tirzepatide

Development Code: LY3298176

Classification: Dual GIP/GLP-1 Receptor Agonist

Peptide Length: 39 Amino Acids

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: Approximately 4,813.5 g/mol

CAS Number: 2023788-19-2

PubChem CID: 156588324

Structural Modification: C20 Fatty Diacid Side Chain

Primary Receptors: GIPR and GLP-1R

Principal Signaling: Gs–cAMP–PKA / EPAC

Research Areas: Incretin Signaling / Glucose Metabolism / Obesity / Body Composition / Cardiometabolic Research

FDA Status: Approved Active Ingredient in Specific Prescription Medicines

ICAME Product Status: Research Use Only

ICAME Pharmacy Product Information

Product Name: Tirzepatide

Alternative Name: LY3298176

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: Dual Incretin Receptor Agonist

Research Areas: GIPR / GLP-1R / Metabolic Signaling / Glucose Homeostasis / Obesity Research

Intended Use: Laboratory Research & Development Only

Product Identity and Quality Verification

Before publication or laboratory use, product specifications should be verified against batch-specific analytical documentation.

Relevant parameters include:

• Verified molecular identity

• Complete modified peptide sequence

• Molecular mass

• Lipid side-chain identification

• Peptide purity

• Peptide content

• Counterion composition

• Impurity profile

• Certificate of Analysis

• Batch identification

• Validated stability information

No claims of pharmaceutical equivalence, sterility, injectable suitability or clinical efficacy should be made without appropriate regulatory authorization and supporting documentation.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, weight-management, diabetes treatment, sleep apnea treatment, bodybuilding, athletic performance enhancement or other clinical purposes. Not for direct administration to humans or animals.

Tirzepatide is a dual GIP/GLP-1 receptor agonist with substantial clinical research evidence.

FDA-approved prescription medicines containing tirzepatide include Mounjaro and Zepbound.

ICAME Pharmacy Tirzepatide is not Mounjaro or Zepbound and is not an FDA-approved pharmaceutical product.

Clinical findings involving approved prescription medicines do not establish the safety, efficacy or suitability of research-grade tirzepatide for human administration.

Information on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, metabolic research, receptor pharmacology, molecular biology and analytical chemistry.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.

Frequently Asked Questions About Tirzepatide

What is Tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors.

What is another name for Tirzepatide?

LY3298176.

How many amino acids does Tirzepatide contain?

39 amino acids.

What is the molecular formula of Tirzepatide?

C₂₂₅H₃₄₈N₄₈O₆₈.

What is the molecular weight of Tirzepatide?

Approximately 4,813.5 g/mol.

What is the CAS number of Tirzepatide?

2023788-19-2.

What is the PubChem CID of Tirzepatide?

What receptors does Tirzepatide activate?

GIPR and GLP-1R.

Is Tirzepatide a GLP-1 receptor agonist?

Yes, but it also activates GIPR, making it a dual incretin receptor agonist.

Is Tirzepatide the same as Semaglutide?

No. Semaglutide selectively activates GLP-1R, while tirzepatide activates GIPR and GLP-1R.

Is Tirzepatide the same as Retatrutide?

No. Retatrutide additionally activates the glucagon receptor.

Is Tirzepatide the same as Survodutide?

No. Survodutide activates GLP-1R and the glucagon receptor.

Does Tirzepatide reduce body weight?

Clinical trials of approved tirzepatide formulations have demonstrated substantial average weight reductions in eligible populations.

What were the SURMOUNT-1 results?

Mean body weight reductions at 72 weeks were approximately 15.0%, 19.5% and 20.9% in the three tirzepatide groups, compared with 3.1% for placebo.

Does Tirzepatide lower HbA1c?

Yes. Clinical studies have demonstrated substantial HbA1c reductions in adults with type 2 diabetes.

Does Tirzepatide affect appetite?

Yes. Reduced appetite and energy intake contribute to its weight-management effects.

Does Tirzepatide delay gastric emptying?

Yes. Tirzepatide can delay gastric emptying.

Does Tirzepatide reduce visceral fat?

Clinical research has demonstrated reductions in abdominal adiposity and related body composition measurements.

Has Tirzepatide been studied for MASH?

Yes. The SYNERGY-NASH phase 2 trial reported improvements in liver histology in the studied population.

Has Tirzepatide been studied for obstructive sleep apnea?

Yes. Clinical research demonstrated improvements in sleep apnea severity in adults with obesity.

Is Tirzepatide FDA-approved?

Yes. It is the active ingredient in FDA-approved prescription medicines, including Mounjaro and Zepbound.

Is research-grade Tirzepatide FDA-approved?

No. The approval of prescription medicines does not extend to independently manufactured research products.

What are the main safety concerns?

Important concerns include gastrointestinal adverse reactions, pancreatitis, gallbladder disease, glucose-related risks, hypersensitivity and thyroid C-cell tumor warnings.

Is Tirzepatide safe during pregnancy?

Zepbound is not appropriate for weight management during pregnancy, and treatment decisions involving approved medicines require medical supervision.

Is ICAME Pharmacy Tirzepatide intended for human use?

No. ICAME Pharmacy Tirzepatide is intended strictly for laboratory research and development purposes.